The 285 references in paper Editorial article , Редакционная статья (2016) “Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации Американской коллегии торакальных врачей и Канадского торакального общества (часть 2-я) // Therapeutic strategy to prevent acute exacerbations of chronic obstructive pulmonary disease: clinical guidelines of American College of Chest Physicians and Canadian Thoracic Society Guideline (Part 2)” / spz:neicon:pulmonology:y:2016:i:3:p:267-291

1
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and pre" vention of chronic obstructive pulmonary disease. Updated 2103. Global Initiative for Chronic Obstructive Lung Disease website. http://www.goldcopd. org/uploads/ users/files/GOLD_Report_2013_Feb20.pdf.Accessed May 15, 2014.
(check this in PDF content)
2
Brusasco V. Reducing cholinergic constriction: the major reversible mechanism in COPD.Eur. Respir. Rev.2006; 15 (99): 32–36. Больные ХОБЛ (старше 40 лет, бывшие или активные курильщики; постбронходилатационный ОФВ1/ ФЖЕЛ < 0,70) Высокий риск обострений ХОБЛ (острое ухудшение с необходимостью назначения АБП и / или системных ГКС: при среднетяжелом – амбулаторно, при тяжелом – в стационаре) Рекомендуется: • ежегодная противогриппоз6 ная вакцинация • легочная реабилитация (обострение ≤4 нед.) • обучение и индивидуаль6 ное ведение при ежемесячном наблюдении Желательно: • пневмококковая вакцинация • отказ от курения • обучение с планом дейст6 вий и индивиду6 альным веде6 нием Нежелательно: • легочная реабилитация (обострение > 4 нед.) • обучение и индивидуаль ное ведени
(check this in PDF content)
3
Cooper C.B. Airflow obstruction and exercise. Respir. Med. 2009; 103 (3): 325–334.
(check this in PDF content)
4
Public Health Agency of Canada. Chronic obstructive pul" monary disease (COPD). Public Health Agency of Canada website. http://www.phac#aspc.gc.ca/cd#mc/crd#mrc/copd# mpoc#eng.php.Accessed June 28, 2012.
(check this in PDF content)
5
Centers for Disease Control and Prevention; National Center for Health Statistics. Deaths: final data for 2009. Natl. Vital. Stat. Rep. 2012; 60 (3): 1–117.
(check this in PDF content)
6
Centers for Disease Control and Prevention; National Center for Health Statistics. National Health Interview Survey Raw Data, 1999–2011. Analysis performed by the American Lung Association Research and Healtheducation Division using SPSS and SUDAAN software. Atlanta GA: Centers for Disease Control and Prevention; 2011.
(check this in PDF content)
7
Mannino D.M., Homa D.M., Akinbami L.J. et al. Centers for Disease Control and Prevention. Chronic obstructive pulmonary disease surveillance – United States, 1971– 2000. MMWR Surveill. Summ.2002; 51 (6): 1–16.
(check this in PDF content)
8
Centers for Disease Control and Prevention; National Center for Health Statistics. National Hospital Discharge Survey Raw Data, 1999–2010. Analysis Performed by the American Lung Association Research and Health" education Division Using SPSS Soft ware. Atlanta GA: Centers for Disease Control and Prevention; 2010.
(check this in PDF content)
9
Confronting COPD in America, 2000. Schulman, Ronca and Bucuvalas, Inc. (SRBI); 2000. Funded by Glaxo SmithKline plc.
(check this in PDF content)
10
Mittmann N., Kuramoto L., Seung S.J. et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir. Med. 2008; 102 (3): 413–421.
(check this in PDF content)
11
Chapman K.R., Bourbeau J., Rance L. The burden of COPD in Canada: results from the Confronting COPD survey. Respir. Med.2003; 97 (Suppl. C): S23–S31.
(check this in PDF content)
12
Connors A.F. Jr, Dawson N.V., Thomas C. et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am. J. Respir. Crit. Care Med. 1996; 154 (4): 959–967.
(check this in PDF content)
13
Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 157 (5): 1418–1422.
(check this in PDF content)
14
Miravitlles M., Murio C., Guerrero T. et al. Pharmaco" economic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest. 2002; 121 (5): 1449–1455.
(check this in PDF content)
15
Miravitlles M., García"Polo C., Domenech A. et al. Cli" nical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease. Lung. 2013; 191 (5): 523–530.
(check this in PDF content)
16
Wouters E.F. Economic analysis of the confronting COPD survey: an overview of results. Respir. Med. 2003; 97 (Suppl. C): S3–S14.
(check this in PDF content)
17
Celli B.R., MacNee W. ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946.
(check this in PDF content)
18
Maltais F., Celli B., Casaburi R. et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respir. Med. 2011; 105 (4): 580–587.
(check this in PDF content)
19
Rodriguez"Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000; 117 (5, Suppl. 2): 398S–401S.
(check this in PDF content)
20
Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary dis" ease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and Euro" pean Respiratory Society. Ann. Intern. Med. 2011; 155 (3): 179–191.
(check this in PDF content)
21
Albert R.K., Connett J., Bailey W.C. et al. COPD Clinical Research Network. Azithromycin for prevention of exacer" bations of COPD. N. Engl. J. Med. 2011; 365 (8): 689–698.
(check this in PDF content)
22
Calverley P., Pauwels R., Vestbo J. et al. Combined salme" terol and fluticasone in the treatment of chronic obstruc" tive pulmonary disease: a randomised controlled trial. Lancet. 2003; 361 (9356): 449–456.
(check this in PDF content)
23
Tashkin D.P., Celli B., Senn S. et al; UPLIFT Study Investigators. A 4"year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359 (15): 1543–1554.
(check this in PDF content)
24
Lewis S.Z., Diekemper R., Ornelas J., Casey K.R. Methodologies for the development of CHEST guidelines and expert panel reports. Chest. 2014; 146 (1): 182–192.
(check this in PDF content)
25
Brouwers M.C., Kho M.E., Browman G.P. et al. AGREE II: advancing guideline development, reporting and evalua" tion in health care. CMAJ. 2010; 182 (18): E839–E842.
(check this in PDF content)
26
Diekemper R., Ireland B., Merz L. P154 development of the Documentation and Appraisal Review Tool (DART) for systematic reviews [poster]. Br. Med. J. Qual. Saf.2013; 22: 61–62.
(check this in PDF content)
27
Higgins J.P.T., Altman D.G., Sterne J.A.C. et al. Chapter 8: assessing risk of bias in included studies. In: Higgins J.P.T., Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. London:The Cochrane Collaboration; 2011.
(check this in PDF content)
28
Downs S.H., Black N. The feasibility of creating a check" list for the assessment of the methodological quality both of randomised and non"randomised studies of health care interventions.J. Epidemiol. Community Health.1998; 52 (6): 377–384.
(check this in PDF content)
29
Langer"Gould A., Popat R.A., Huang S.M. et al. Clinical and demographic predictors of long"term disability in patients with relapsing"remitting multiple sclerosis: a sys" tematic review. Arch. Neurol. 2006; 63 (12): 1686–1691.
(check this in PDF content)
30
Aaron S.D., Fergusson D., Marks G.B. et al. Counting, analysing and reporting exacerbations of COPD in ran" domised controlled trials. Thorax. 2008; 63 (2): 122–128.
(check this in PDF content)
31
Balshem H., Helfand M., Schünemann H.J. et al. GRADE guidelines: 3. Rating the quality of evidence. J. Clin. Epidemiol.2011; 64 (4): 401–406.
(check this in PDF content)
32
Guyatt G., Gutterman D., Baumann M.H. et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. Chest. 2006; 129 (1): 174–181.
(check this in PDF content)
33
Graham I.D., Logan J., Harrison M.B. et al. Lost in knowledge translation: time for a map? J. Contin. Educ. Health Prof. 2006; 26 (1): 13–24.
(check this in PDF content)
34
Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness. JAMA. 2002; 288 (14): 1775–1779.
(check this in PDF content)
35
Bodenheimer T., Wagner E.H., Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, part 2. JAMA. 2002; 288 (15): 1909–1914.
(check this in PDF content)
36
Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update). National Institute for Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации CHEST / CTS 284 Health and Care Excellence website. http://guidance.nice. org.uk/CG101/Guidance/pdf/English.Accessed May 15, 2014.
(check this in PDF content)
37
O’Donnell D.E., Aaron S., Bourbeau J. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease"2007 update. Can. Respir. J.2007; 14 (Suppl. B): 5B–32B.
(check this in PDF content)
38
Disler R.T., Inglis S.C., Davidson P.M. Non"pharmaco" logical management interventions for COPD: an overview of Cochrane systematic reviews (protocol). Cochrane Database Syst. Rev.2013; (2): CD010384.
(check this in PDF content)
39
Kruis A.L., Smidt N., Assendelft W.J.J. et al. Integrated disease management interventions for patients with chron" ic obstructive pulmonary disease. Cochrane Database Syst. Rev.2011; (10): CD009437.
(check this in PDF content)
40
Krumholz H.M., Currie P.M., Riegel B. et al. A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. Circulation. 2006; 114 (13): 1432–1445.
(check this in PDF content)
41
Craig P., Dieppe P., Macintyre S. et al. Research Council Guidance. Developing and evaluating complex interven" tions: the new Medical Research Council guidance. Br. Mer. J. 2008; 337: a1655.
(check this in PDF content)
42
Petticrew M. When are complex interventions ‘complex’? When are simple interventions ‘simple’? Eur. J. Public. Health.2011; 21 (4): 397–398.
(check this in PDF content)
43
Weightman A., Ellis S., Cullum A. et al. Grading Evidence and Recommendations for Public Health Interventions: Developing and Piloting a Framework. London: Health Development Agency; 2005.
(check this in PDF content)
44
Vaccines and immunizations. Centers for Disease Control and Prevention website. http://www.cdc.gov/vaccines/vpd# vac/pneumo. Accessed March 3, 2014.
(check this in PDF content)
45
Lee T.A., Weaver F.M., Weiss K.B. Impact of pneumococ" cal vaccination on pneumonia rates in patients with COPD and asthma. J. Gen. Intern. Med.2007; 22 (1): 62–67.
(check this in PDF content)
46
Centers for Disease Control and Prevention; Advisory Committee on Immunization Practices. Updated recom" mendations for prevention of invasive pneumococcal dis" ease among adults using 23"valent pneumococcal polysac" charide vaccine (PPSV23). Morb. Mortal. Wkly Rep. 2010; 59 (34): 1102–1106.
(check this in PDF content)
47
Bogaert D., van der Valk P., Ramdin R. et al. Host" pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect. Immun. 2004; 72 (2): 818–823.
(check this in PDF content)
48
Patel I.S., Seemungal T.A.R., Wilks M. et al. Relationship between bacterial colonisation and the frequency, charac" ter, and severity of COPD exacerbations. Thorax. 2002; 57 (9): 759–764.
(check this in PDF content)
49
Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pul" monary disease.N. Engl. J. Med.2002; 347 (7): 465–471.
(check this in PDF content)
50
Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173 (10): 1114–1121.
(check this in PDF content)
51
WHO recommendations for routine immunization sum" mary tables. World Health Organization website. http:// www.who.int/immunization/policy/immunization_tables/en. Accessed March 3, 2014.
(check this in PDF content)
52
Walters J.A., Smith S., Poole P. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2010; (11): CD001390.
(check this in PDF content)
53
Dransfield M.T., Harnden S., Burton R.L. al. Long"term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin. Infect. Dis.2012; 55 (5): e35–e44.
(check this in PDF content)
54
Furumoto A., Ohkusa Y., Chen M. et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26 (33): 4284–4289.
(check this in PDF content)
55
Fiore A.E., Uyeki T.M., Broder K. et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Rec. Rep.2010; 59 (RR"8): 1–62.
(check this in PDF content)
56
Centanni S., Pregliasco F., Bonfatti C. et al. Clinical effi" cacy of a vaccine"immunostimulant combination in the prevention of influenza in patients with chronic obstruc" tive pulmonary disease and chronic asthma. J. Chemother. 1997; 9 (4): 273–278.
(check this in PDF content)
57
Monto A.S. Influenza: quantifying morbidity and mortal" ity. Am. J. Med.1987; 82 (6A): 20–25.
(check this in PDF content)
58
Poole P., Chacko E.E., Wood"Baker R., Cates C.J. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2006; (1): CD002733.
(check this in PDF content)
59
Howells C.H., Tyler L.E. Prophylactic use of influenza vaccine in patients with chronic bronchitis. A pilot trial. Lancet. 1961; 278 (7218): 1428–1432.
(check this in PDF content)
60
Wongsurakiat P., Maranetra K.N., Wasi C. et al. Acute res" piratory illness in patients with COPD and the effective" ness of influenza vaccination: a randomized controlled study. Chest. 2004; 125 (6): 2011–2020.
(check this in PDF content)
61
Fletcher C., Peto R. The natural history of chronic airflow obstruction. Br. Med. J.1977; 1 (6077): 1645–1648.
(check this in PDF content)
62
Hersh C.P., DeMeo D.L., Al"Ansari E. et al. Predictors of survival in severe, early onset COPD. Chest. 2004; 126 (5): 1443–1451.
(check this in PDF content)
63
Scanlon P.D., Connett J.E., Waller L.A. et al. Smoking cessation and lung function in mild"to"moderate chronic obstructive pulmonary disease. The Lung Health Study. Am. J. Respir. Crit. Care Med. 2000; 161 (2): 381–390.
(check this in PDF content)
64
Kanner R.E., Connett J.E., Williams D.E., Buist A.S. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pul" monary disease: the Lung Health Study. Am. J. Med. 1999; 106 (4): 410–416.
(check this in PDF content)
65
Makris D., Moschandreas J., Damianaki A. et al. Exacer" bations and lung function decline in COPD: new insights in current and ex"smokers. Respir. Med. 2007; 101 (6): 1305–1312.
(check this in PDF content)
66
Tashkin D., Kanner R., Bailey W. et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double"blind, placebo"controlled, randomised trial. Lancet. 2001; 357 (9268): 1571–1575.
(check this in PDF content)
67
Jiménez"Ruiz C.A., Masa F., Miravitlles M. et al. Smoking characteristics: diff erences in attitudes and dependence between healthy smokers and smokers with COPD. Chest. 2001; 119 (5): 1365–1370.
(check this in PDF content)
68
Strassmann R., Bausch B., Spaar A. et al. Smoking cessa" tion interventions in COPD: a network metaanalysis of randomised trials. Eur. Respir. J.2009; 34 (3): 634–640.
(check this in PDF content)
69
Meer R.M., Wagena E.J., Ostelo R.W. et al. Smoking cessation for chronic obstructive pulmonary dis" ease.Cochrane Database Syst. Rev. 2003; (2): CD002999.
(check this in PDF content)
70
Tønnesen P., Carrozzi L., Fagerström K.O. et al. Smoking cessation in patients with respiratory diseases: a high prior" ity, integral component of therapy.Eur. Respir. J. 2007; 29 (2): 390–417.
(check this in PDF content)
71
Au D.H., Bryson C.L., Chien J.W. et al. The effects of smoking cessation on the risk of chronic obstructive pul" monary disease exacerbations. J. Gen. Intern. Med. 2009; 24 (4): 457–463.
(check this in PDF content)
72
Christenhusz L.C., Prenger R., Pieterse M.E. et al. Cost" effectiveness of an intensive smoking cessation interven" tion for COPD outpatients. Nicotine Tob. Res.2012; 14 (6): 657–663.
(check this in PDF content)
73
Borglykke A., Pisinger C., Jørgensen T., Ibsen H. The effectiveness of smoking cessation groups offered to hospi" talised patients with symptoms of exacerbations of chron" ic obstructive pulmonary disease (COPD). Clin. Respir. J. 2008; 2 (3): 158–165.
(check this in PDF content)
74
Godtfredsen N.S., Vestbo J., Osler M., Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax. 2002; 57 (11): 967–972.
(check this in PDF content)
75
Szabo E., Mao J.T., Lam S. et al. Chemoprevention of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence" based clinical practice guidelines. Chest. 2013; 143 (5, Suppl.): e40S–e60S.
(check this in PDF content)
76
Spruit M.A., Singh S.J., Garvey C. et al; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society / European Respiratory Society state" ment: key concepts and advances in pulmonary rehabilita" tion. Am. J. Respir. Crit. Care Med. 2013; 188 (8): e13–e64.
(check this in PDF content)
77
Marciniuk D.D., Brooks D., Butcher S. et al. Optimizing pulmonary rehabilitation in chronic obstructive pul" monary disease – practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can. Respir. J. 2010; 17 (4): 159–168.
(check this in PDF content)
78
Ries A.L., Bauldoff G.S., Carlin B.W. et al. Pulmonary rehabilitation: Joint ACCP/AACVPR evidence"based clinical practice guidelines. Chest. 2007; 131 (5, Suppl.): 4S–42S.
(check this in PDF content)
79
Lacasse Y., Goldstein R., Lasserson T.J., Martin S. Pulmo" nary rehabilitation for chronic obstructive pulmonary dis" ease. Cochrane Database Syst. Rev. 2006; (4): CD003793.
(check this in PDF content)
80
Lacasse Y., Wong E., Guyatt G.H. et al. Meta"analysis of respiratory rehabilitation in chronic obstructive pul" monary disease. Lancet. 1996; 348 (9035): 1115–1119.
(check this in PDF content)
81
Nici L., ZuWallack R. An official American Thoracic Society workshop report: the integrated care of the COPD patient.Proc. Am. Thorac. Soc. 2012; 9 (1): 9–18.
(check this in PDF content)
82
Ko F.W., Dai D.L., Ngai J. et al. Effect of early pulmonary rehabilitation on health care utilization and health status in patients hospitalized with acute exacerbations of COPD. Respirology. 2011; 16 (4): 617–624.
(check this in PDF content)
83
Behnke M., Taube C., Kirsten D. et al. Home"based exer" cise is capable of preserving hospital"based improvements in severe chronic obstructive pulmonary disease. Respir. Med. 2000; 94 (12): 1184–1191.
(check this in PDF content)
84
Murphy N., Bell C., Costello R.W. Extending a home from hospital care programme for COPD exacerbations to include pulmonary rehabilitation. Respir. Med. 2005; 99 (10): 1297–1302.
(check this in PDF content)
85
Ringbaek T., Brondum E., Martinez G. et al. Long"term effects of 1"year maintenance training on physical func" tioning and health status in patients with COPD: a ran" domized controlled study. J. Cardiopulm. Rehabil. Prev. 2010; 30 (1): 47–52.
(check this in PDF content)
86
Román M., Larraz C., Gómez A. et al. Efficacy of pul" monary rehabilitation in patients with moderate chronic obstructive pulmonary disease: a randomized controlled trial. BMC Fam. Pract. 2013; 14: 21.
(check this in PDF content)
87
Man W.D., Polkey M.I., Donaldson N. et al. Community pulmonary rehabilitation after hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: randomised controlled study. Br. Med. J. 2004; 329 (7476): 1209.
(check this in PDF content)
88
Seymour J.M., Moore L., Jolley C.J. et al. Outpatient pul" monary rehabilitation following acute exacerbations of COPD. Thorax. 2010; 65 (5): 423–428.
(check this in PDF content)
89
Boxall A.M., Barclay L., Sayers A., Caplan G.A. Managing chronic obstructive pulmonary disease in the community. A randomized controlled trial of home"based pulmonary rehabilitation for elderly housebound patients. J. Cardiopulm. Rehabil. 2005; 25 (6): 378–385.
(check this in PDF content)
90
Eaton T., Young P., Fergusson W. et al. Does early pulmo" nary rehabilitation reduce acute health"care utilization in COPD patients admitted with an exacerbation? A random" ized controlled study. Respirology. 2009; 14 (2): 230–238.
(check this in PDF content)
91
Puhan M.A., Gimeno"Santos E., Scharplatz M. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2011; (10): CD005305.
(check this in PDF content)
92
Wagner E.H. Chronic disease management: what will it take to improve care for chronic illness? Eff. Clin. Pract. 1998; 1 (1): 2–4.
(check this in PDF content)
93
Case Management Society of America. What is a case manager? Case Management Society of America website. http://www.cmsa.org/Home/CMSA/WhatisaCaseManager/ tabid/224/Default.aspx. Accessed March 18, 2014.
(check this in PDF content)
94
Zwerink M., Brusse"Keizer M., van der Valk P.D. et al. Self management for patients with chronic obstructive pul" monary disease.Cochrane Database Syst. Rev. 2014; (3): CD002990.
(check this in PDF content)
95
Jarab A.S., Alqudah S.G., Khdour M. et al. Impact of pharmaceutical care on health outcomes in patients with COPD. Int. J. Clin. Pharmacol. 2012; 34 (1): 53–62.
(check this in PDF content)
96
Farrero E., Escarrabill J., Prats E. et al. Impact of a hospi" tal"based home"care program on the management of COPD patients receiving long"term oxygen therapy. Chest. 2001; 119 (2): 364–369.
(check this in PDF content)
97
Lainscak M., Kadivec S., Kosnik M. et al. Discharge coor" dinator intervention prevents hospitalizations in patients with COPD: a randomized controlled trial. J. Am. Med. Dir. Assoc. 2013; 14 (6): 450.e1–450.e6.
(check this in PDF content)
98
Smith B.J., Appleton S.L., Bennett P.W. et al. The effect of a respiratory home nurse intervention in patients with chronic obstructive pulmonary disease (COPD). Aust. N. Z. J. Med.1999; 29 (5): 718–725.
(check this in PDF content)
99
Soler J.J., Martínez"García M.A., Román P. et al. Effectiveness of a specific program for patients with chronic obstructive pulmonary disease and frequent exacerbations. Arch. Bronconeumol.2006; 42 (10): 501–508 (in Spanish).
(check this in PDF content)
100
Gallefoss F. The effects of patient education in COPD in a 1"year follow"up randomised, controlled trial. Patient Educ. Couns.2004; 52 (3): 259–266.
(check this in PDF content)
101
McGeoch G.R., Willsman K.J., Dowson C.A. et al. Self" management plans in the primary care of patients with chronic obstructive pulmonary disease. Respirology. 2006; 11 (5): 611–618.
(check this in PDF content)
102
Wakabayashi R., Motegi T., Yamada K. et al. Efficient integrated education for older patients with chronic Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации CHEST / CTS 286 obstructive pulmonary disease using the Lung Information Needs Questionnaire.Geriatr. Gerontol. Int.2011; 11 (4): 422–430.
(check this in PDF content)
103
Wood"Baker R., McGlone S., Venn A., Walters E.H. Written action plans in chronic obstructive pulmonary dis" ease increase appropriate treatment for acute exacerba" tions. Respirology. 2006; 11 (5): 619–626.
(check this in PDF content)
104
Bourbeau J., Julien M., Maltais F. et al. Chronic Obstructive Pulmonary Disease axis of the Respiratory Network Fonds de la Recherche en Santédu Québec. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a diseasespecific self"man" agement intervention. Arch. Intern. Med. 2003; 163 (5): 585–591.
(check this in PDF content)
105
Casas A., Troosters T., Garcia"Aymerich J. et al. Integ" rated care prevents hospitalisations for exacerbations in COPD patients. Eur. Respir. J. 2006; 28 (1): 123–130.
(check this in PDF content)
106
Fan V.S., Gaziano J.M., Lew R. et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, con" trolled trial.Ann. Intern. Med. 2012; 156 (10): 673–683.
(check this in PDF content)
107
Khdour M.R., Kidney J.C., Smyth B.M., McElnay J.C. Clinical pharmacy"led disease and medicine management programme for patients with COPD. Br. J. Clin. Pharma# col. 2009; 68 (4): 588–598.
(check this in PDF content)
108
Rea H., McAuley S., Stewart A. et al. A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern. Med. J. 2004; 34 (11): 608–614.
(check this in PDF content)
109
Rice K.L., Dewan N., Bloomfield H.E. et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial.Am. J. Respir. Crit. Care Med.2010; 182 (7): 890–896.
(check this in PDF content)
110
Trappenburg J.C., Monninkhof E.M., Bourbeau J. et al. Effect of an action plan with ongoing support by a case manager on exacerbation"related outcome in patients with COPD: a multicenter randomised controlled trial. Thorax. 2011; 66 (11): 977–984.
(check this in PDF content)
111
Walters J., Cameron"Tucker H., Wills K. et al. Effects of telephone health mentoring in community"recruited chronic obstructive pulmonary disease on self"manage" ment capacity, quality of life and psychological morbidity: a randomised controlled trial. Br. Med. J. Open.2013; 3 (9): e003097.
(check this in PDF content)
112
Bischoff E.W., Akkermans R., Bourbeau J. et al. Compre" hensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. Br. Med. J. 2012; 345: e7642.
(check this in PDF content)
113
Coultas D., Frederick J., Barnett B. et al. A randomized trial of two types of nurse"assisted home care for patients with COPD. Chest. 2005; 128 (4): 2017–2024.
(check this in PDF content)
114
Gadoury M.A., Schwartzman K., Rouleau M. et al; Chronic Obstructive Pulmonary Disease axis of the Respiratory Health Network, Fonds de la recherche en Santédu Québec (FRSQ). Self"management reduces both short" and long"term hospitalisation in COPD.Eur. Respir. J. 2005; 26 (5): 853–857.
(check this in PDF content)
115
Hermiz O., Comino E., Marks G. et al. Randomised con" trolled trial of home based care of patients with chronic obstructive pulmonary disease. Br. Med. J. 2002; 325 (7370): 938.
(check this in PDF content)
116
Telemedicine: opportunities and developments in member states. Report on the second global survey on eHealth. World Health Organization website. http://www.who.int/ goe/ publications/goe_telemedicine_2010.pdf.Accessed March 13, 2014.
(check this in PDF content)
117
What is telemedicine? American Telemedicine Association website. http://www.americantelemed.org/about#telemedicine/ what#is#telemedicine.Accessed March 13, 2014.
(check this in PDF content)
118
Toledo P., Jiménez S., del Pozo F. et al. Telemedicine experience for chronic care in COPD. IEEE Trans. Inf. Technol. Biomed. 2006; 10 (3): 567–573.
(check this in PDF content)
119
Vitacca M., Bianchi L., Guerra A. et al. Tele"assistance in chronic respiratory failure patients: a randomised clinical trial. Eur. Respir. J. 2009; 33 (2): 411–418.
(check this in PDF content)
120
Wong K.W., Wong F.K., Chan M.F. Effects of nurse"initi" ated telephone follow"up on self"efficacy among patients with chronic obstructive pulmonary disease. J. Adv. Nurs. 2005; 49 (2): 210–222.
(check this in PDF content)
121
McLean S., Nurmatov U., Liu J.L. et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; (7): CD007718.
(check this in PDF content)
122
Antoniades N.C., Rochford P.D., Pretto J.J. et al. Pilot study of remote telemonitoring in COPD. Telemed. J. E. Health. 2012; 18 (8): 634–640.
(check this in PDF content)
123
Chau J.P., Lee D.T., Yu D.S. et al. A feasibility study to investigate the acceptability and potential effectiveness of a telecare service for older people with chronic obstructive pulmonary disease. Int. J. Med. Inform. 2012; 81 (10): 674–682.
(check this in PDF content)
124
Dinesen B., Haesum L.K., Soerensen N. et al. Using pre" ventive home monitoring to reduce hospital admission rates and reduce costs: a case study of telehealth among chronic obstructive pulmonary disease patients.J. Tele# med. Telecare.2012; 18 (4): 221–225.
(check this in PDF content)
125
Gellis Z.D., Kenaley B., McGinty J. et al. Outcomes of a telehealth intervention for homebound older adults with heart or chronic respiratory failure: a randomized con" trolled trial. Gerontologist. 2012; 52 (4): 541–552.
(check this in PDF content)
126
Haesum L.K., Soerensen N., Dinesen B. et al. Cost"utili" ty analysis of a telerehabilitation program: a case study of COPD patients.Telemed. J. E. Health.2012; 18 (9): 688–692.
(check this in PDF content)
127
Halpin D.M., Laing"Morton T., Spedding S. et al. A ran" domized controlled trial of the effect of automated inter" active calling combined with a health risk forecast on fre" quency and severity of exacerbations of COPD assessed clinically and using EXACT PRO. Prim. Care Respir. J. 2011; 20 (3): 324–331.
(check this in PDF content)
128
Henderson C., Knapp M., Fernández J.L. et al. Cost effectiveness of telehealth for patients with long term con" ditions (Whole Systems Demonstrator telehealth ques" tionnaire study): nested economic evaluation in a prag" matic, cluster randomised controlled trial. Br. Med. J. 2013; 346: f1035.
(check this in PDF content)
129
Holland A. Telehealth reduces hospital admission rates in patients with COPD.J. Physiother.2013; 59 (2): 129.
(check this in PDF content)
130
Jódar"Sánchez F., Ortega F., Parra C. et al. Imple" mentation of a telehealth programme for patients with severe chronic obstructive pulmonary disease treated with long"term oxygen therapy.J. Telemed. Telecare.2013; 19 (1): 11–17.
(check this in PDF content)
131
Koff P.B., Jones R.H., Cashman J.M. et al. Proactive inte" grated care improves quality of life in patients with COPD. Eur. Respir. J. 2009; 33 (5): 1031–1038.
(check this in PDF content)
132
Lewis K.E., Annandale J.A., Warm D.L. et al. Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD. 2010; 7 (1): 44–50.
(check this in PDF content)
133
ParéG., Poba"Nzaou P., Sicotte C. et al. Comparing the costs of home telemonitoring and usual care of chronic obstructive pulmonary disease patients: a randomized con" trolled trial. Eur. Res. Telemed.2013; 2 (2): 35–47.
(check this in PDF content)
134
Pedone C., Chiurco D., Scarlata S., Incalzi R.A. Efficacy of multiparametric telemonitoring on respiratory out" comes in elderly people with COPD: a randomized con" trolled trial. BMC Health Serv. Res. 2013; 13: 82.
(check this in PDF content)
135
Pinnock H., Hanley J., Lewis S. et al. The impact of a telemetric chronic obstructive pulmonary disease moni" toring service: randomised controlled trial with economic evaluation and nested qualitative study. Prim. Care Respir. J. 2009; 18 (3): 233–235.
(check this in PDF content)
136
Shany T., Hession M., Pryce D. et al. Home telecare study for patients with chronic lung disease in the Sydney West Area Health Service. Stud. Health Technol. Inform. 2010; 161: 139–148.
(check this in PDF content)
137
Sorknaes A.D., Madsen H., Hallas J. et al. Nurse tele" consultations with discharged COPD patients reduce early readmissions"an interventional study.Clin. Respir. J. 2011; 5 (1): 26–34.
(check this in PDF content)
138
Steventon A., Bardsley M., Billings J. et al. Effect of tele" health on use of secondary care and mortality: findings from the Whole System Demonstrator cluster randomised trial.Br. Med. J.2012; 344: e3874.
(check this in PDF content)
139
Venter A., Burns R., Hefford M., Ehrenberg N. Results of a telehealth"enabled chronic care management service to support people with long"term conditions at home. J. Telemed. Telecare.2012; 18 (3): 172–175.
(check this in PDF content)
140
Wootton R. Twenty years of telemedicine in chronic dis" ease management – an evidence synthesis. J. Telemed. Telecare. 2012; 18 (4): 211–220.
(check this in PDF content)
141
Kew K.M., Mavergames C., Walters J.A. Long"acting beta2"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2013; (10): CD010177.
(check this in PDF content)
142
Vestbo J., Hurd S.S., AgustíA.G. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summa" ry. Am. J. Respir. Crit. Care Med.2013; 187 (4): 347–365.
(check this in PDF content)
143
Barr R.G., Bourbeau J., Camargo C.A., Ram F.S. Tiotro" pium for stable chronic obstructive pulmonary disease: A meta"analysis. Thorax. 2006; 61 (10): 854–862.
(check this in PDF content)
144
Singh S., Loke Y.K., Enright P.L., Furberg C.D. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta"analysis of randomised controlled trials. Br. Med. J.2011; 342: d3215.
(check this in PDF content)
145
Wise R.A., Anzueto A., Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N. Engl. J. Med. 2013; 369 (16): 1491–1501.
(check this in PDF content)
146
Karner C., Chong J., Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; (7): CD009285.
(check this in PDF content)
147
O′Donnell D.E., Hernandez P., Kaplan A. et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can. Respir. J. 2008; 15 (Suppl. A): 1A–8A.
(check this in PDF content)
148
O′Donnell D.E., Flüge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J.2004; 23 (6): 832–840.
(check this in PDF content)
149
Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003; 124 (5): 1743–1748.
(check this in PDF content)
150
O′Donnell D.E., Voduc N., Fitzpatrick M., Webb K.A. Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease. Eur. Respir. J. 2004; 24 (1): 86–94.
(check this in PDF content)
151
Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med.2007; 356 (8): 775–789.
(check this in PDF content)
152
Chong J., Karner C., Poole P. Tiotropium versus long"act" ing beta"agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2012; (9): CD009157.
(check this in PDF content)
153
Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium ver" sus salmeterol for the prevention of exacerbations of COPD.N. Engl. J. Med.2011; 364 (12): 1093–1103.
(check this in PDF content)
154
Appleton S., Jones T., Poole P. et al. Ipratropium bromide versus long"acting beta"2 agonists for stable chronic obstructive pulmonary disease.Cochrane Database Syst. Rev.2006; (3): CD006101.
(check this in PDF content)
155
Brown D. et al. A randomized, double blind, parallel, multi"centre comparison of inhalation solution with albuterol inhalation solution following single"dose and chronic administration (85 days) in patients with chronic obstructive pulmonary disease. Boehringer Ingelheim unpublished report USA U91"0865; 1991.
(check this in PDF content)
156
Brown D. et al. A randomized, double blind, parallel, mul" ticenter comparison of Atrovent (ipratropium bromide) inhalation solution with metaproterenol inhalation solu" tion following single"dose and chronic administration (85 days) in patient with chronic obstructive pulmonary disease. Boehringer Ingelheim unpublished report USA U91"0866; 1991.
(check this in PDF content)
157
Friedman M. A multicenter study of nebulized bron" chodilator solutions in chronic obstructive pulmonary dis" ease.Am. J. Med. 1996; 100 (Suppl. 1): S30–S39.
(check this in PDF content)
158
Rennard S.I., Serby C.W., Ghafouri M. et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: A retrospective analysis of data from seven clinical trials. Chest. 1996; 110 (1): 62–70.
(check this in PDF content)
159
Tashkin D.P., Ashutosh K., Bleecker E.R. et al. Compa" rison of the anticholinergic bronchodilator ipratropium bromide with metaproterenol in chronic obstructive pul" monary disease. A 90"day multi"center study. Am. J. Med. 1986; 81 (5A): 81–90.
(check this in PDF content)
160
Tashkin D.P., Bleecker E., Braun S. et al. Results of a mul" ticenter study of nebulized inhalant bronchodilator solu" tions.Am. J. Med. 1996; 100 (Suppl. 1): S62–S69.
(check this in PDF content)
161
COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85"day multicenter trial. Chest. 1994; 105 (5): 1411–1419.
(check this in PDF content)
162
COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997; 112 (6): 1514–1521.
(check this in PDF content)
163
Colice G.L. Nebulized bronchodilators for outpatient management of stable chronic obstructive pulmonary dis" ease. Am. J. Med. 1996; 100 (Suppl. 1): S11–S18.
(check this in PDF content)
164
Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base.Arch. Intern. Med.1999; 159 (2): 156–160.
(check this in PDF content)
165
Alexander K.M. et al. A randomized, double blind, paral" lel, multicenter comparison of Combivent (ipratropium bromide and albuterol sulfate) inhalation solution with its components following single"dose and chronic adminis" Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации CHEST / CTS 288 tration (85 days) in patients with chronic pulmonary dis" ease. Boehringer Ingelheim unpublished report: USA U92"0801; 1992.
(check this in PDF content)
166
Gross N., Tashkin D., Miller R et al. Inhalation by nebu" lization of albuterol"ipratropium combination (Dey com" bination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration. 1998; 65 (5): 354–362.
(check this in PDF content)
167
Levin D.C., Little K.S., Laughlin K.R. et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta"2 agonists in patients with chronic obstructive pulmonary disease. Am. J. Med.1996; 100 (Suppl. 1): S40–S48.
(check this in PDF content)
168
Noord J.A., Bantje T.A., Eland M.E. et al. A ran" domised controlled comparison of tiotropium and iprat" ropium in the treatment of chronic obstructive pulmonary disease. Thorax. 2000; 55(4): 289–294.
(check this in PDF content)
169
Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999; 115 (4): 957–965.
(check this in PDF content)
170
Cramer J.A., Bradley"Kennedy C., Scalera A. Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. Can. Respir. J.2007; 14 (1): 25–29.
(check this in PDF content)
171
O’Donnell D.E., Revill S.M., Webb K.A. Dynamic hyper" inflation and exercise intolerance in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2001; 164 (5): 770–777.
(check this in PDF content)
172
Anthonisen N.R., Connett J.E., Kiley J.P. et al. Effects of smoking intervention and the use of an inhaled anticholin" ergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994; 272 (19): 1497–1505.
(check this in PDF content)
173
Cheyne L., Irvin"Sellers M.J., White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2013; (9): CD009552.
(check this in PDF content)
174
Loke Y.K., Singh S., Furberg C.D. Tiotropium and the risk of death in COPD. N. Engl. J. Med.2014; 370 (5): 480–481.
(check this in PDF content)
175
Verhamme K.M., van Blijderveen N., Sturkenboom M.C. Tiotropium and the risk of death in COPD. N. Engl. J. Med. 2014; 370 (5): 481–482.
(check this in PDF content)
176
Jenkins C.R. Tiotropium and the risk of death in COPD. N. Engl. J. Med.2014; 370 (5): 482–483.
(check this in PDF content)
177
Sethi S., Mahler D.A., Marcus P. et al. Inflammation in COPD: implications for management.Am. J. Med.2012; 125 (12): 1162–1170.
(check this in PDF content)
178
Izquierdo Alonso J.L., Rodíguez Glez"Moro J.M. The excessive use of inhaled corticosteroids in chronic obstruc" tive pulmonary disease. Arch. Bronconeumol.2012; 48 (6): 207–212.
(check this in PDF content)
179
Miguel"Díez J., Carrasco"Garrido P., Rejas"Gutierrez J. et al. Inappropriate overuse of inhaled corticosteroids for COPD patients: impact on health costs and health status. Lung. 2011; 189 (3): 199–206.
(check this in PDF content)
180
Barnes P.J. Inhaled corticosteroids in COPD: a controver" sy. Respiration. 2010; 80 (2): 89–95.
(check this in PDF content)
181
Price D., Yawn B., Brusselle G., Rossi A. Risk"to"benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J.2013; 22 (1): 92–100.
(check this in PDF content)
182
Zervas E., Samitas K., Gaga M. et al. Inhaled corticos" teroids in COPD: pros and cons. Curr. Drug Targets.2013; 14 (2): 192–224.
(check this in PDF content)
183
Barnes P.J. Role of HDAC2 in the pathophysiology of COPD. Ann. Rev. Physiol. 2009; 71: 451–464.
(check this in PDF content)
184
Barnes P.J. Glucocorticosteroids: current and future direc" tions.Br. J. Pharmacol. 2011; 163 (1): 29–43.
(check this in PDF content)
185
Mercado N., Thimmulappa R., Thomas C.M.R. et al. Decreased histone deacetylase 2 impairs Nrf2 activation by oxidative stress. Biochem. Biophys. Res. Commun. 2011; 406 (2): 292–298.
(check this in PDF content)
186
Jen R., Rennard S.I., Sin D.D. Effects of inhaled corti" costeroids on airway inflammation in chronic obstructive pulmonary disease: a systematic review and meta"analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2012; 7: 587–595.
(check this in PDF content)
187
Anzueto A., Ferguson G.T., Feldman G. et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009; 6 (5): 320–329.
(check this in PDF content)
188
Boscia J.A., Pudi K.K., Zvarich M.T. et al. Effect of once" daily fluticasone furoate/vilanterol on 24"hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three"way, incomplete block, crossover study. Clin. Ther.2012; 34 (8): 1655–1666.
(check this in PDF content)
189
Burge P.S., Calverley P.M.A., Jones P.W. et al. Rando" mised, double blind, placebo controlled study of fluticas" one propionate in patients with moderate to severe chron" ic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J.2000; 320 (7245): 1297–1303.
(check this in PDF content)
190
Calverley P.M., Boonsawat W., Cseke Z. et al. Main" tenance therapy with budesonide and formoterol in chron" ic obstructive pulmonary disease. Eur. Respir. J. 2003; 22 (6): 912–919.
(check this in PDF content)
191
Dransfield M.T., Bourbeau J., Jones P.W. et al. Once"daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two repli" cate double"blind, parallel"group, randomised controlled trials.Lancet Respir. Med. 2013; 1 (3): 210–223.
(check this in PDF content)
192
Ferguson G.T., Anzueto A., Fei R. et al. Effect of fluticas" one propionate/salmeterol (250/50 mg) or salmeterol (50 mg) on COPD exacerbations.Respir. Med. 2008; 102 (8): 1099–1108.
(check this in PDF content)
193
Hanania N.A., Darken P., Horstman D. et al. The effica" cy and safety of fluticasone propionate (250 mg) / salme" terol (50 mg) combined in the Diskus inhaler for the treat" ment of COPD. Chest. 2003; 124(3): 834–843.
(check this in PDF content)
194
Kerwin E.M., Scott"Wilson C., Sanford L. et al. A ran" domised trial of fluticasone furoate/vilanterol (50/25 mg; 100/25 mg) on lung function in COPD. Respir. Med. 2013; 107 (4): 560–569.
(check this in PDF content)
195
Lapperre T.S., Snoeck"Stroband J.B., Gosman M.M.E. et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann. Intern. Med. 2009; 151 (8): 517–527.
(check this in PDF content)
196
Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination deliv" ered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2002; 166 (8): 1084–1091.
(check this in PDF content)
197
Martinez F.J., Boscia J., Feldman G. et al. Fluticasone furoate/vilanterol (100/25; 200/25 mg) improves lung function in COPD: a randomised trial.Respir. Med. 2013; 107 (4): 550–559.
(check this in PDF content)
198
Sharafkhaneh A., Southard J.G., Goldman M. et al. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double"blind, randomized study.Respir. Med.2012; 106 (2): 257–268.
(check this in PDF content)
199
Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.Eur. Respir. J.
(check this in PDF content)
200
21 (1): 74–81. 200. Agarwal R., Aggarwal A.N., Gupta D., Jindal S.K. Inhaled corticosteroids vs placebo for preventing COPD exacerba" tions: a systematic review and metaregression of random" ized controlled trials. Chest. 2010; 137 (2): 318–325.
(check this in PDF content)
201
Glaab T., Taube C. Effects of inhaled corticosteroids in stable chronic obstructive pulmonary disease. Pulm. Pharmacol. Ther.2011; 24 (1): 15–22.
(check this in PDF content)
202
Spencer S., Karner C., Cates C.J., Evans D.J. Inhaled cor" ticosteroids versus long"acting beta"2"agonists for chronic obstructive pulmonary disease.Cochrane Database Syst. Rev. 2011; 12: CD007033.
(check this in PDF content)
203
Grunsven P.M., van Schayck C.P., Derenne J.P. et al. Long term effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a meta"analysis. Thorax. 1999; 54 (1): 7–14.
(check this in PDF content)
204
Yang I.A., Clarke M.S., Sim E.H., Fong K.M. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst. Rev.2012; 7: CD002991.
(check this in PDF content)
205
Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of twice"daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40 (4): 830–836.
(check this in PDF content)
206
Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once"daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143 (5): 317–326.
(check this in PDF content)
207
Cazzola M., Di Marco F., Santus P. et al. The pharmaco" dynamics effects of single inhaled doses of formoterol, tiotropium and their combination in patients with COPD. Pulm. Pharmacol. Ther.2004; 17 (1): 35–39.
(check this in PDF content)
208
Gross N.J., Nelson H.S., Lapidus R.J. et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir. Med.2008; 102 (2): 189–197.
(check this in PDF content)
209
Tashkin D.P., Cooper C.B. The role of long"acting bron" chodilators in the management of stable COPD. Chest. 2004; 125 (1): 249–259.
(check this in PDF content)
210
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Canadian Thoracic Society / Canadian Respiratory Clinical Research Consortium. Tiotropium in combina" tion with placebo, salmeterol, or fluticasonesalmeterol for treatment of chronic obstructive pulmonary disease: a ran" domized trial. Ann. Intern. Med. 2007; 146 (8): 545–555.
(check this in PDF content)
211
Brusasco V., Hodder R., Miravitlles M. et al. Health out" comes following treatment for 6 months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax.2006; 61 (1): 91.
(check this in PDF content)
212
Barnes P.J., Pocock S.J., Magnussen H. et al. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design. Pulm. Pharmacol. Ther. 2010; 23 (3): 165–171.
(check this in PDF content)
213
Beier J., Chanez P., Martinot J.B. et al. Safety, tolerability and efficacy of indacaterol, a novel once"daily beta"2"ago" nist, in patients with COPD: a 28"day randomised, place" bo controlled clinical trial. Pulm. Pharmacol. Ther.2007; 20 (6): 740–749.
(check this in PDF content)
214
Jones P.W., Mahler D.A., Gale R. et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir. Med. 2011; 105 (6): 892–899.
(check this in PDF content)
215
Cazzola M., Santus P., Di Marco F. et al. Bronchodilator effect of an inhaled combination therapy with salmeterol 1 fluticasone and formoterol 1 budesonide in patients with COPD. Respir. Med. 2003; 97 (5): 453–457.
(check this in PDF content)
216
Jones P.W., Willits L.R., Burge P.S., Calverley P.M. Inhaled Steroids in Obstructive Lung Disease in Europe study investigators. Disease severity and the effect of fluti" casone propionate on chronic obstructive pulmonary dis" ease exacerbations. Eur. Respir. J.2003; 21 (1): 68–73.
(check this in PDF content)
217
Vestbo J., Soriano J.B., Anderson J.A. et al. Gender does not influence the response to the combination of salme" terol and fluticasone propionate in COPD. Respir. Med. 2004; 98 (11): 1045–1050.
(check this in PDF content)
218
Calverley P.M. Reducing the frequency and severity of exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc.2004; 1 (2): 121–124.
(check this in PDF content)
219
Rodrigo G.J., Plaza V., Castro"Rodríguez J.A. Com" parison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm. Pharmacol. Ther.2012; 25 (1): 40–47.
(check this in PDF content)
220
Nannini L.J., Lasserson T.J., Poole P. Combined corticos" teroid and long"acting beta(2)"agonist in one inhaler ver" sus long"acting beta(2)"agonists for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2012; 9: CD006829.
(check this in PDF content)
221
Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopy" rronium and tiotropium (SPARK): a randomised, double" blind, parallel"group study. Lancet Respir. Med.2013; 1 (3): 199–209.
(check this in PDF content)
222
He Z.Y., Ou L.M., Zhang J.Q. et al. Effect of 6 months of erythromycin treatment on inflammatory cells in induced sputum and exacerbations in chronic obstructive pul" monary disease. Respiration. 2010; 80 (6): 445–452.
(check this in PDF content)
223
Seemungal T.A., Wilkinson T.M., Hurst J.R. et al. Long" term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med.2008; 178 (11): 1139–1147.
(check this in PDF content)
224
Aaron S.D., Vandemheen K.L., Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N. Engl. J. Med. 2003; 348 (26): 2618–2625.
(check this in PDF content)
225
Davies L., Angus R.M., Calverley P.M. Oral corticos" teroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomized controlled trial. Lancet. 1999; 354 (9177): 456–460.
(check this in PDF content)
226
Niewoehner D.E., Erbland M.L., Deupree R.H. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 1999; 340 (25): 1941–1947.
(check this in PDF content)
227
Thompson W.H., Nielson C.P., Carvalho P. et al. Cont" rolled trial of oral prednisone in outpatients with acute COPD exacerbation. Am. J. Respir. Crit. Care Med. 1996; 154 (2): 407–412.
(check this in PDF content)
228
Aggarwal P., Wig N., Bhoi S. Efficacy of two corticosteroid regimens in acute exacerbation of chronic obstructive pul" monary disease. Int. J. Tuberc. Lung Dis.2011; 15 (5): 687–692.
(check this in PDF content)
229
Ställberg B., Selroos O., Vogelmeier C. et al. Budesonide/ formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double"blind, ran" domised, non"inferiority, parallel"group, multicentre study. Respir. Res. 2009; 10: 11.
(check this in PDF content)
230
Rice K.L., Rubins J.B., Lebahn F. et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial. Am. J. Respir. Crit. Care Med. 2000; 162 (1): 174–178.
(check this in PDF content)
231
Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pul" Хроническая обструктивная болезнь легких: профилактика обострений. Клинические рекомендации CHEST / CTS 290 monary disease: two randomised clinical trials. Lancet. 2009; 374 (9691): 685–694.
(check this in PDF content)
232
Fabbri L.M., Calverley P.M., Izquierdo"Alonso J.L. et al. Roflumilast in moderate"to"severe chronic obstructive pulmonary disease treated with longacting bronchodila" tors: two randomised clinical trials. Lancet. 2009; 374 (9691): 695–703.
(check this in PDF content)
233
Lee S.D., Hui D.S., Mahayiddin A.A. et al. Roflumilast in Asian patients with COPD: a randomized placebo"con" trolled trial. Respirology. 2011; 16 (8): 1249–1257.
(check this in PDF content)
234
Rabe K.F., Magnussen H., Dent G. Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants.Eur. Respir. J.1995; 8 (4): 637–642.
(check this in PDF content)
235
Rossi A., Kristufek P., Levine B.E. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry pow" der and oral, slow"release theophylline in the treatment of COPD. Chest. 2002; 121 (4): 1058–1069.
(check this in PDF content)
236
Zhou Y., Wang X., Zeng X. et al. Positive benefits of theo" phylline in a randomized, double"blind, parallel"group, placebo"controlled study of low"dose, slow"release theo" phylline in the treatment of COPD for 1 year. Respirology. 2006; 11 (5): 603–610.
(check this in PDF content)
237
Sheffner A.L., Medler E.M., Jacobs L.W., Sarett H.P. The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine. Am. Rev. Respir. Dis.1964; 90: 721–729.
(check this in PDF content)
238
Boman G., Bäcker U., Larsson S. et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur. J. Respir. Dis. 1983; 64 (6): 405–415.
(check this in PDF content)
239
Grassi C., Morandini G.C. A controlled trial of intermit" tent oral acetylcysteine in the long"term treatment of chronic bronchitis. Eur. J. Clin. Pharmacol.1976; 9 (5–6): 393–396.
(check this in PDF content)
240
Hansen N.C., Skriver A., Brorsen"Riis L. et al. Orally administered N"acetylcysteine may improve general well" being in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535.
(check this in PDF content)
241
Pela R., Calcagni A.M., Subiaco S. et al. N"acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD. Respiration. 1999; 66 (6): 495–500.
(check this in PDF content)
242
Zheng J.P., Wen F.Q., Bai C.X. et al. Twice daily N"acetyl" cysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double" blind placebo"controlled trial. Lancet Respir. Med.2014; 2 (3): 187–194.
(check this in PDF content)
243
British Thoracic Society Research Committee. Oral N"acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax. 1985; 40 (11): 832–835.
(check this in PDF content)
244
Decramer M., Rutten"van Mölken M., Dekhuijzen P.N. et al. Effects of N"acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost"Utility Study, BRONCUS): a randomised placebo"controlled trial. Lancet. 2005; 365 (9470): 1552–1560.
(check this in PDF content)
245
Dueholm M., Nielsen C., Thorshauge H. et al. N"acetyl" cysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi"centre study. Respir. Med. 1992; 86 (2): 89–92.
(check this in PDF content)
246
Parr G.D., Huitson A. Oral Fabrol (oral N"acetyl"cys" teine) in chronic bronchitis. Br. J. Dis. Chest.1987; 81 (4): 341–348.
(check this in PDF content)
247
Rasmussen J.B., Glennow C. Reduction in days of illness aft erlongterm treatment with N"acetylcysteine con" trolled"release tablets in patients with chronic bronchitis. Eur. Respir. J. 1988; 1 (4): 351–355.
(check this in PDF content)
248
Schermer T., Chavannes N., Dekhuijzen R. et al. Flu" ticasone and N"acetylcysteine in primary care patients with COPD or chronic bronchitis. Respir. Med. 2009; 103 (4): 542–551.
(check this in PDF content)
249
Moretti M., Bottrighi P., Dallari R. et al. The effect of long"term treatment with erdosteine on chronic obstruc" tive pulmonary disease: the EQUALIFE Study. Drugs Exp. Clin. Res.2004; 30 (4): 143–152.
(check this in PDF content)
250
Braga P.C., Allegra L., Rampoldi C. et al. Longlasting effects on rheology and clearance of bronchial mucus aft ershort"term administration of high doses of carbocys" teine"lysine to patients with chronic bronchitis. Respira# tion. 1990; 57 (6): 353–358.
(check this in PDF content)
251
Allegra L., Cordaro C.I., Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with car" bocysteine lysine salt monohydrate: a multicenter, double" blind, placebo"controlled trial. Respiration. 1996; 63 (3): 174–180.
(check this in PDF content)
252
Grillage M., Barnard"Jones K. Long"term oral carbocis" teine therapy in patients with chronic bronchitis. A double blind trial with placebo control. Br. J. Clin. Pract. 1985; 39 (10): 395–398.
(check this in PDF content)
253
Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocis" teine on acute exacerbation of chronic obstructive pul" monary disease (PEACE Study): a randomised placebo" controlled study. Lancet. 2008; 371 (9629): 2013–2018.
(check this in PDF content)
254
Bartziokas K., Papaioannou A.I., Minas M. et al. Statins and outcome after hospitalization for COPD exacerbation: a prospective study.Pulm. Pharmacol. Ther. 2011; 24 (5): 625–631.
(check this in PDF content)
255
Blamoun A.I., Batty G.N., DeBari V.A. et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retro" spective cohort study. Int. J. Clin. Pract. 2008; 62 (9): 1373–1378.
(check this in PDF content)
256
Huang C.C., Chan W.L., Chen Y.C. et al. Statin use and hospitalization in patients with chronic obstructive pul" monary disease: a nationwide population"based cohort study in Taiwan.Clin. Ther. 2011; 33 (10): 1365–1370.
(check this in PDF content)
257
Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin"converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol.2006; 47 (12): 2554–2560.
(check this in PDF content)
258
Wang M.T., Lo Y.W., Tsai C.L. et al. Statin use and risk of COPD exacerbation requiring hospitalization. Am. J. Med. 2013; 126 (7): 598–606.
(check this in PDF content)
259
Criner G.J., Connett J.E., Aaron S.D. et al. COPD Clinical Research Network; Canadian Institutes of Health Research. Simvastatin for the prevention of exacerbations in moderate"to"severe COPD.N. Engl. J. Med.2014; 370 (23): 2201–2210.
(check this in PDF content)
260
Casarosa P., Kollak I., Kiechle T. et al. Functional and biochemical rationales for the 24"hour"long duration of action of olodaterol.J. Pharmacol. Exp. Ther.2011; 337 (3): 600–609.
(check this in PDF content)
261
Noord J.A., Smeets J.J., Drenth B.M. et al. 24"hour bronchodilation following a single dose of the novel β"2"agonist olodaterol in COPD. Pulm. Pharmacol. Ther. 2011; 24 (6): 666–672.
(check this in PDF content)
262
Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bron" chodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494.
(check this in PDF content)
263
Cazzola M., Calzetta L., Matera M.G. β"2"adrenoceptor agonists: current and future direction. Br. J. Pharmacol. 2011; 163 (1): 4–17.
(check this in PDF content)
264
Cazzola M., Matera M.G. Emerging inhaled bronchodila" tors: an update.Eur. Respir. J.2009; 34 (3): 757–769.
(check this in PDF content)
265
Cazzola M., Molimard M. The scientifi c rationale for combining long"acting beta2"agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther.2010; 23 (4): 257–267.
(check this in PDF content)
266
Cazzola M., Rogliani P., Matera M.G. Aclidinium bro" mide/formoterol fumarate fixed"dose combination for the treatment of chronic obstructive pulmonary disease. Exp. Opin. Pharmacother. 2013; 14 (6): 775–781.
(check this in PDF content)
267
Cazzola M., Rogliani P., Segreti A., Matera M.G. An update on bronchodilators in phase I and II clinical trials. Exp. Opin. Invest. Drugs. 2012; 21 (10): 1489–1501.
(check this in PDF content)
268
Dahl R., Chapman K.R., Rudolf M. et al. Safety and effi" cacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study. Respir. Med. 2013; 107 (10): 1558–1567.
(check this in PDF content)
269
Mak G., Hanania N.A. New bronchodilators.Curr. Opin. Pharmacol.2012; 12 (3): 238–245.
(check this in PDF content)
270
Matera M.G., Calzetta L., Segreti A., Cazzola M. Emerg" ing drugs for chronic obstructive pulmonary disease. Exp. Opin. Emerg. Drugs.2012; 17 (1): 61–82.
(check this in PDF content)
271
Matera M.G., Page C.P., Cazzola M. Novel bronchodila" tors for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol.Sci. 2011; 32 (8): 495–506.
(check this in PDF content)
272
Maele B., Fabbri L.M., Martin C. et al. Cardio" vascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients. COPD. 2010; 7 (6): 418–427.
(check this in PDF content)
273
Noord J.A., Buhl R., Laforce C. et al. QVA149 de" monstrates superior bronchodilation compared with inda" caterol or placebo in patients with chronic obstructive pul" monary disease. Thorax. 2010; 65 (12): 1086–1091.
(check this in PDF content)
274
Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once"daily QVA149 compared with twice" daily salmeterolfluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a ran" domised, double"blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.
(check this in PDF content)
275
Donohue J.F., Maleki"Yazdi M.R., Kilbride S. et al. Efficacy and safety of once"daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir. Med. 2013; 107 (10): 1538–1546.
(check this in PDF content)
276
Feldman G., Walker R.R., Brooks J. et al. 28"day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo"controlled trial.Pulm. Pharmacol. Ther. 2012; 25 (6): 465–471.
(check this in PDF content)
277
Kelleher D.L., Mehta R.S., Jean"Francois B.M. et al. Safety, tolerability, pharmacodynamics and pharmacoki" netics of umeclidinium and vilanterol alone and in combi" nation: a randomized crossover trial. PLoS One.2012; 7 (12): e50716.
(check this in PDF content)
278
Mehta R., Kelleher D., Preece A. et al. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open"label study. Int. J. Chron. Obstruct. Pulm. Dis.2013; 8: 159–167.
(check this in PDF content)
279
Lötvall J., Bakke P.S., Bjermer L. et al. Efficacy and safe" ty of 4 weeks’ treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo"controlled randomised trial. Br. Med. J. Open. 2012; 2 (1): e000370.
(check this in PDF content)
280
Traynor K. Fluticasone"vilanterol combination approved for COPD. Am. J. Health Syst. Pharm.2013; 70 (12): 1008.
(check this in PDF content)
281
Vestbo J., Anderson J., Brook R.D. et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. Eur. Respir. J.2013; 41 (5): 1017–1022.
(check this in PDF content)
282
Barnes P.J. New therapies for chronic obstructive pul" monary disease. Med. Princ. Pract. 2010; 19 (5): 330–338.
(check this in PDF content)
283
Barnes P.J. Development of new drugs for COPD. Curr. Med. Chem.2013; 20 (12): 1531–1540.
(check this in PDF content)
284
Cazzola M., Ciaprini C., Page C.P, Matera M.G. Target" ing systemic inflammation: novel therapies for the treat" ment of chronic obstructive pulmonary disease.Exp. Opin. Ther. Targets.2007; 11 (10): 1273–1286.
(check this in PDF content)
285
Cazzola M., Page C.P., Calzetta L., Matera M.G. Emerg" ing antiinflammatory strategies for COPD. Eur. Respir. J. 2012; 40 (3): 724–741. Поступила 06.05.16 УДК 616.246036.126084(072)
(check this in PDF content)